Experts discuss tailored approaches to neoadjuvant therapy for esophageal and G-junction cancers, emphasizing the importance of multidisciplinary care.
Final overall survival and the association of pathological outcomes with event-free survival in MATTERHORN: A randomised, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel in resectable gastric / gastroesophageal junction adenocarcinoma
Explore the evolving landscape of cancer treatment strategies, focusing on guideline-based management and the impact of multimodal approaches on patient outcomes.
Advertisement
Advertisement
Trending on CancerNetwork
1
All-Oral Revumenib Regimen May Show Advantage in Newly Diagnosed AML
2
Blinatumomab/Ponatinib Provides Chemo-Free Option in Ph+ ALL
3
Epcoritamab Combo Significantly Improves Efficacy in 2L R/R Follicular Lymphoma
4
Azacitidine Plus Venetoclax Improves EFS in Acute Myeloid Leukemia
5
